Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar-Apr;70(2):145-53.
doi: 10.4103/0250-474X.41446.

Strategies for enhanced drug delivery to the central nervous system

V S N M Dwibhashyam  1 , A N Nagappa
Affiliations

Strategies for enhanced drug delivery to the central nervous system

V S N M Dwibhashyam et al. Indian J Pharm Sci. 2008 Mar-Apr.

Abstract

Treating central nervous system diseases is very challenging because of the presence of a variety of formidable obstacles that impede drug delivery. Physiological barriers like the blood-brain barrier and blood-cerebrospinal fluid barrier as well as various efflux transporter proteins make the entry of drugs into the central nervous system very difficult. The present review provides a brief account of the blood brain barrier, the P-glycoprotein efflux and various strategies for enhancing drug delivery to the central nervous system.

Keywords: CNS drug delivery; blood brain barrier; nano particles; p-glycoprotein.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic comparison between brain and general capillaries. The epithelium in brain capillaries are thickened with fat which acts as tight junctions and barrier for water soluble molecules in systemic circulation.
Fig. 2
Fig. 2
The lock-in mechanism for a brain chemical drug delivery system (CDDS). Lipid soluble drug after entering the brain gets converted into less lipid soluble drug by metabolic conversion. The formed metabolite gets entrapped in the brain, which ensures longer residence leading to longer duration of action and targeting action. T- Targeter moiety (lipophilic form); D- drug; F- modifier function; T+- Targeter moiety (hudrophilic form).
Fig. 3
Fig. 3
Transferrin transporter-based chemical peptide delivery. Peptide like drugs (VIPa) can be delivered to the brain by conjugating them to monoclonal antibodies (TfCRMab) by utilizing transporters such as transferrin transporter. TfT- transferring transporter; TfcRMab- antitransferrin receptor monoclonal antibody; SPDP- N-succinimidyl-3-(2-pyridyldithio)propionate; VIPa- vasoactive intestinal peptide analog.
Fig. 4
Fig. 4
The Olfactory pathway between nose and central nervous system. Drugs can be delivered to the CNS by using olfactory route prevailing between nose and brain.
Fig. 5
Fig. 5
Structural Similarity between PNA and DNA oligomers. The molecular mimicry of DNA into Polyamide (peptide) nucleic acids (PNAs) has helped the delivery of the chimeric peptide to intra cranial delivery.
See this image and copyright information in PMC

References

    1. Martin B, Robert L, Henry B, Mathiowitz E. Encyclopedia of controlled drug delivery. Vol. 1. New York: John Wiley and Sons Inc; 1999. pp. 184–210.
    1. Pardridge WM. Recent advances in blood-brain barrier transport. Annu Rev Pharmacol Toxicol. 1988;28:25–39. - PubMed
    1. Tamargo RJ, Brem H. Transporting therapeutics across the blood-brain barrier. Neurosurg. 1992;2:259–79.
    1. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today. 1996;3:106–13. - PubMed
    1. Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, et al. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly (butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett. 2002;126:131–41. - PubMed

LinkOut - more resources